Loading…
Loading…
Toronto, Ontario--(Newsfile Corp. - Le 29 mai/May 2025) - The common shares of Cognetivity Neurosciences Ltd. will be delisted from the CSE at market close today, May 29, 2025.
Latest Peer-Reviewed Study Published in Frontiers in Public Health Highlights Cost-Efficiency and Improved Clinical Outcomes from Using Cognetivity's Proprietary CognICA(TM) Technology, Showing Savings of Over £40 Million Per Year Compared with Traditional Cognitive Assessment Tools in Primary and Secondary Care Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leader in artificial intelligence (AI) powered cognitive assessment technology, is delighted to announce the peer-reviewed publication of the health economic impact of its CognICATM technology in the journal Frontiers in Public Health.
Collaboration With Highly Rated Healthcare Provider Opens US Healthcare Market for Brain Health for AI Powered CognICA, Enabling Patient Access to Latest Alzheimer's Drugs Vancouver, British Columbia--(Newsfile Corp. - October 11, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading artificial intelligence (AI) healthcare technology company is delighted to announce a collaboration with UC Health, one of the leading healthcare systems in the United States, to improve early detection of cognitive impairment in clinical settings in the USA.
Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated Care Vancouver, British Columbia--(Newsfile Corp. - October 3, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading AI healthcare technology company, is delighted to announce a collaboration with the Mediclinic Group ("Mediclinic"), a prominent international private hospital group operating across Europe, the Middle East and Southern Africa.
New Approach to Measuring Impact of Counselling to Deliver Next Generation Care to Mental Health Sufferers in North America Vancouver, British Columbia--(Newsfile Corp. - September 21, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading artificial intelligence (AI) healthcare technology company is delighted to announce a partnership with No Fear Counselling, the leading and rapidly growing Vancouver-based counselling practice with over 150 therapists and a network of 60 locations.
CognICA Chosen as Winner of Best AI Product in Healthcare Award at CogX Festival Vancouver, British Columbia--(Newsfile Corp. - September 13, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading artificial intelligence (AI) healthcare technology company is delighted to announce that it has won a major AI technology award, with the company's CognICA™ platform being recognised in the CogX Awards as the Best AI Product in Healthcare for 2023.
CognICA Shortlisted for Most Innovative AI Product in Healthcare Award at CogX Festival Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading artificial intelligence (AI) healthcare technology company is pleased to announce that it has been shortlisted for a major AI technology award, with the company's CognICATM platform being recognised in the CogX Awards in the Most Innovative AI Product in the Healthcare category.
Cognetivity's Landmark ADePT Study, Funded by the UK Innovation Agency and Published in Leading Neuroscience Journal Demonstrates Unprecedented Sensitivity in Detecting Cognitive Impairment in Early Stage Alzheimer's Disease, Essential for Treatment With New Drugs Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE.1UB) ("the Company" or "Cognetivity") a leading artificial intelligence (AI) healthcare technology company is pleased to announce the peer-reviewed publication of its groundbreaking Accelerating Dementia Pathway Technologies (ADePT) Study in the journal Frontiers in Aging Neuroscience - a leading academic journal on brain aging and associated diseases.
No recent filings indexed.